We will establish the best facility

State of the art mass production with leading technology to ensure both quality and efficacy

Quality science-driven research and manufacturing to meet global (US) needs

Our operations focus on manufacturing and packaging Sterile Injectables and Opthalmics processes.

Quality science-driven research and manufacturing to meet global (US) needs

Our operations focus on manufacturing and packaging Sterile Injectables and Opthalmics processes.

Opening Hours

  • Monday
    8:00am – 7:00pm
  • Tuesday
    8:00am- 7:00pm
  • Wednesday
    8:00am – 7:00pm
  • Thursday
    8:00am- 77:00pm
  • Friday
    8:00am- 7:00am
  • Saturday
    7:30am – 4:00pm
  • Sunday
    Closed

    Company Ownership

    AmSterGen Holding Company LLC owns 100% of the two subsidiary companies.

    Investors Pool Target:  10 to 25 MM

    We are currently engaged and working with prospective investors (both from the US and from India) who showed a tremendous amount of interest to participate

    Meet Our Team

    Management Team

    our Services

    Where We Focus Most

    Currently, there are four niche areas AmSterGen will focus its attention

    Injectables

    Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore t dolore magna aliqua.

    Ophthalmics

    Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore t dolore magna aliqua.

    Contract Development and Manufacturing Services

    Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore t dolore magna aliqua.

    Semi-Solids and Liquids

    Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore t dolore magna aliqua.

    WHO WE ARE

    Choose The Best Quality Products

    We provide our customers with innovative, high-quality products.

    AmSterGen Life Sciences Holding Company, LLC is a holding company comprised of three organizations, Amstergen Life Sciences LLC (operating company), Amstergen CDMO Services LLC, and Amstergen Fixed Assets  LLC (TBD). The AmSterGen Holding Company will be a vertically integrated pharmaceutical company encompassing all aspects of market research, product selection, product research and development, manufacturing, packaging, and logistics/distribution.


    Raju V.K. Vegesna

    (Ph.D., CEO)

    Operations

    Our operations focus on manufacturing and packaging Sterile Injectables and Ophthalmics processes.

    Best In Industry

    AmSterGen Life Sciences Holding Company, LLC is a holding company comprised of three organizations, Amstergen Life Sciences LLC (operating company), Amstergen CDMO Services LLC, and Amstergen Fixed Assets  LLC (TBD). The AmSterGen Holding Company will be a vertically integrated pharmaceutical company encompassing all aspects of market research, product selection, product research and development, manufacturing, packaging, and logistics/distribution.

    The AmSterGen Holding company will be a 130,000 sq/ft facility located at Building #1, Franklin Development Centre, 720 Johnsville Boulevard, Warminster, Bucks County, Pennsylvania (PA 18974).

    AmSterGen’s senior management will have more than 100 years of combined proven expertise in the industry. 

      CEO

      Dr. Vegesna brings over 35 years of pharmaceutical experience. Starting his career in 1986, for the first 15 years, He worked for companies such as GSK, BASF, and Johnson & Johnson (McNeil Consumer Products), most notably in formulation development, product development, Technology Transfer, manufacturing, and compliance.  While working, Dr. Vegesna has received numerous awards for developing innovative formulations. He left J&J in 2001 and started his interest in entrepreneurship.  He co-founded LiquiSource Inc (2001-2003) and Allan Pharmaceutical Inc (2004-2008) and successfully sold these companies. He joined with Kevin Connolly, CEO, VersaPharm Inc (a Georgia-based company that acquired Allan Pharmaceuticals) as part of his senior management team in 2008 and developed several ANDAs. In 2014, VersaPharm was successfully sold to Akorn, Inc. In 2017, He partnered with Kevin Connolly and co-founded Douglas Pharma US Inc in affiliation with Douglas Pharmaceuticals, a New Zealand-based company. He developed several ANDAs for the last 4 years for US markets and managed a successful US FDA inspection recently for Douglas Pharma US Inc.

      Dr. Vegesna holds an MS in Pharmacy from Andhra University, India, and an MS and Ph.D. in Pharmaceutical Sciences from the University of British Columbia, Vancouver, Canada.

      Advisor and Board of Directors

      Mr. Connolly brings over 30 years of finance and management experience in Pharmaceuticals. Notably, He was the CFO for Taro Pharmaceuticals for 13 years where he increased the market cap from $25 million to $2.5 billion. He Co-founded VersaPharm Inc in 2006 by partnering with TailWind Investment Group. Under his leadership as CEO, He grew the company and successfully sold it to Akorn Inc in 2014 for 440 million. In 2017, He partnered with Dr. Raju Vegesna and co-founded Douglas Pharma US, Inc as an affiliate of Douglas Pharmaceuticals, a New Zealand-based parent company. Under his leadership as President from 2017 to 2021, he established a prominent US presence for Douglas.

      He has been on board with a few other pharmaceutical companies and investment groups. Kevin is a graduate of Fordham University and holds a CPA.

      Vice President, Manufacturing Operations, Facility Maintenance And Logistics

      View full profile

      Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

      Director, Projects Management

      Dr. Sagar Vegesna brings 8 years of professional experience in the Pharmacy and HealthCare areas. He finished his Under Graduate and Doctorate degrees in  Pharmacy from Northeastern University, Boston in 2013. He joined Walgreens Pharmacy in 2013 in Boston and worked in retail Pharmacy as well as retail Pharmacy management with Walgreens. After spending two years there, in 2015, he moved to Baltimore and joined Johns Hopkins Hospital in their Pharmacy Operations Division. He has grown in ranks and currently working as Operations Lead for their specialty pharmacy department. While working, he pursued and completed his MBA from Johns Hopkins Carey Business School with a focus on entrepreneurship and healthcare administration.